MASTERINVEST Kapitalanlage GmbH Has $5.32 Million Holdings in Merck & Co., Inc. $MRK

MASTERINVEST Kapitalanlage GmbH lessened its position in Merck & Co., Inc. (NYSE:MRK) by 10.6% in the first quarter, HoldingsChannel reports. The fund owned 44,247 shares of the company’s stock after selling 5,225 shares during the quarter. MASTERINVEST Kapitalanlage GmbH’s holdings in Merck & Co., Inc. were worth $5,322,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of MRK. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $25,000. Abound Financial LLC bought a new position in Merck & Co., Inc. in the 4th quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $26,000. High Note Wealth LLC boosted its stake in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $133.94.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA expanded approval for Merck’s Keytruda in combination with Pfizer’s Padcev for muscle-invasive bladder cancer, broadening the drug’s potential use and strengthening Keytruda’s growth outlook. FDA Expands MRK & PFE’s Keytruda-Padcev Combo Use in Bladder Cancer
• Positive Sentiment: Several Wall Street firms raised price targets on Merck, including JPMorgan, BMO Capital Markets, and Guggenheim, reflecting stronger confidence in the company’s pipeline and earnings power. Analyst price target updates
• Neutral Sentiment: Investors are also watching Merck’s upcoming earnings report, with expectations centered on whether Keytruda growth and other business trends can offset pressure from patent-cliff concerns and slower mature-drug sales. Earnings preview: What to expect from Merck & Co.’s report
• Neutral Sentiment: Merck is also being discussed by traders as a potential value play and as a company facing a future Keytruda patent cliff, which keeps long-term sentiment mixed despite recent positives. Why Merck Stock Is in the Spotlight Today

Merck & Co., Inc. Stock Performance

MRK stock opened at $120.91 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm has a market cap of $298.62 billion, a PE ratio of 34.06, a P/E/G ratio of 3.12 and a beta of 0.19. The business has a 50 day moving average of $119.28 and a 200-day moving average of $116.60. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $130.29.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the company posted $2.22 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 4.35 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.